Completing data — refresh the page later to see the latest
60645-00-3CCC(=O)N(c1ccccc1)[C@]1(C(=O)OC)CCN(CCc2ccccc2)C[C@@H]1CIMYHGORQCPYVBZ-NBGIEHNGSA-NLofentanil is an analog of fentanyl and is one of the most potent opioids available today. It displays most similarity to carfentanil (4-carbomethoxyfentanyl) and is considered to be slightly more potent than this drug.
log Kow = 4.22
4.22
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
SRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.
TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 30,000(SRC), determined from a structure estimation method(2), indicates that lofentanil is expected to be immobile in soil(SRC). The estimated pKa of lofentanil is 8.36(3), indicating that this compound will exist partially in the cation form in the environment and cations generally adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4). Volatilization of the cation form from moist soil is not expected because cations do not volatilize(SRC). Volatilization of neutral lofentanil from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of 5.8X10-13 atm-cu m/mole(SRC), using a fragment constant estimation method(2). Lofentanil is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 3.5X10-10 mm Hg at 25 °C(SRC), determined from a fragment constant method(2). Biodegradation data in soil were not available(SRC, 2017).
The aim of the present study was to describe the activity of a set of opioid drugs, including partial agonists, in a cell system expressing only mu opioid receptors. Receptor activation was assessed by measuring the inhibition of forskolin-stimulated cyclic adenosine mono phosphate (cAMP) production. Efficacies and potencies of these ligands were determined relative to the endogenous ligand beta-endorphin and the common mu agonist, morphine. Among the ligands studied naltrexone, WIN 44,441 and SKF 10047, were classified as antagonists, while the remaining ligands were agonists. Agonist efficacy was assessed by determining the extent of inhibition of forskolin-stimulated cAMP production. The rank order of efficacy of the agonists was fentanyl = hydromorphone = beta-endorphin > etorphine = lofentanil = butorphanol = morphine = nalbuphine = nalorphine > cyclazocine = dezocine = metazocine >or= xorphanol. The rank order of potency of these ligands was different from that of their efficacies; etorphine > hydromorphone > dezocine > xorphanol = nalorphine = butorphanol = lofentanil > metazocine > nalbuphine > cyclazocine > fentanyl > morphine >>>> beta-endorphin. These results elucidate the relative activities of a set of opioid ligands at mu opioid receptor and can serve as the initial step in a systematic study leading to understanding of the mode of action of opioid ligands at this receptor. Furthermore, these results can assist in understanding the physiological effect of many opioid ligands acting through mu opioid receptors.
We determined the binding domains of sufentanil and lofentanil in the mu opioid receptor by comparing their binding affinities to seven mu/delta and six mu/kappa chimeric receptors with those to mu, delta and kappa opioid receptors. TMHs 6 and 7 and the e3 loop of the mu opioid receptor were important for selective binding of sufentanil and lofentanil to the mu over the kappa receptor. TMHs 1-3 and the e1 loop of the mu opioid receptor conferred binding selectivity for sufentanil over the delta receptor. Thus, the region that conferred binding selectivity for sufentanil differs, depending on chimeras used. In addition, the interaction TMHs 1-3 and TMHs 6-7 was crucial for the high affinity binding of these two ligands. These two regions are likely to contain sites of interaction with the ligands or to confer conformations specific to the mu receptor.
Nociceptin (orphanin FQ) is the recently discovered peptide agonist for the orphan receptor opioid receptor-like 1 (ORL1). Despite the high sequence homology between ORL1 and the opioid receptors, most opioids lack affinity for the nociceptin receptor. The affinity and functional profile of opioids possessing activity at the nociceptin receptor was determined using (3)H-nociceptin and nociceptin-stimulated (35)S-GTPgammaS binding. The mu-opioid receptor-selective agonist lofentanil potently and competitively displaced [3H]nociceptin at rat brain receptors (IC(50) 62 nM). Lofentanil exhibited full agonism for enhancement of (35)S-GTPgammaS binding to human recombinant ORL1 receptors (EC(50) 50 nM). The related piperidines ohmefentanyl and sufentanil and the nonselective opioid receptor agonist etorphine were less potent nociceptin receptor agonists. The kappa(1)+kappa(3)-opioid receptor agonist/mu-opioid receptor antagonist naloxone benzoylhydrazone was a pure antagonist at both rat brain and human ORL1 receptors. The nonselective opioid receptor partial agonist buprenorphine and the nonselective opioid receptor antagonist (-)-quadazocine exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors. Thus, opioids displaying full agonism at the nociceptin receptor are also opioid receptor agonists, whereas opioids that are antagonists or partial agonists at the nociceptin receptor show antagonism or partial agonism at opioid receptors. In addition, the stereospecificity required at opioid receptors appears to be retained at the nociceptin receptor, since (+)-quadazocine is inactive at both receptors. These findings illustrate the structural and functional homology of the opioid recognition site on these two receptor classes and suggest that opioids may provide leads for the design of nonpeptide nociceptin receptor agonists and antagonists lacking affinity for the classical opioid receptors.
60645-00-3、61380-40-3DTXSID201016402CHEMBL3990749AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 30,000(SRC), determined from a structure estimation method(2), indicates that lofentanil is expected to adsorb to suspended solids and sediment(SRC). An estimated pKa of 8.36(3) indicates lofentanil will exist partially in the cation form at pH values of 5 to 9 and, therefore, volatilization of the cation from water surfaces is not expected to be an important fate process(SRC). Volatilization from water surfaces of neutral lofentanil is not expected(4) based upon an estimated Henry's Law constant of 5.8X10-13 atm-cu m/mole(SRC), developed using a fragment constant estimation method(2). Lofentanil is not expected to undergo hydrolysis in the environment based on estimated hydrolysis half-lives of 160,000 and 16,000 years at pH values of 7 and 8, respectively(2). According to a classification scheme(5), an estimated BCF of 280(SRC), from its log Kow of 4.22(6) and a regression-derived equation(2), suggests the potential for bioconcentration in aquatic organisms is high. Biodegradation data in water were not available(SRC, 2017).
ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), lofentanil, which has an estimated vapor pressure of 3.5X10-10 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase lofentanil may be removed from the air by wet and dry deposition(SRC). Lofentanil contains chromophores that absorb at wavelengths >290 nm(3) and, therefore, may be susceptible to direct photolysis by sunlight(SRC).
IDENTIFICATION AND USE: Lofentanil is a very potent opioid analgesic. It is used clinically in the management of pain. However, the high analgesic potency of this drug is limited by the development of tolerance after chronic use. HUMAN STUDIES: In patients side effects of very low incidence included nausea, vomiting and sedation. Another study mentions drowsiness in three patients as a side effect. ANIMAL STUDIES: Increasing doses of lofentanil (0, 0.08, 0.16, 0.31, 0.63, 1.25, 2.50, 5.00, and 10.0 ug/kg) were administered intravenously to rats to examine the relationship among central nervous system (CNS) depressant dosage, degree of analgesia (inhibition of tail withdrawal reflex), anesthesia (no response to bone-crush injury), and CNS opiate-receptor occupancy. Increasing doses of lofentanil produce increasing analgesia and anesthesia and eventually complete opiate receptor occupancy. Analgesia occurs with doses of lofentanil (0.31 ug/kg) that result in levels of CNS opiate-receptor binding too low to be measured and anesthesia occurs with doses of lofentanil (1.25 ug/kg) that produce occupancy of about 25% of the available opiate receptors in subcortical areas and cortex. In rats a dose eight times the anesthetic dose of lofentanil is needed to saturate virtually all available CNS opiate receptors (10.0 ug/kg).
Using a structure estimation method based on molecular connectivity indices(1), the Koc of lofentanil can be estimated to be 30,000(SRC). According to a classification scheme(2), this estimated Koc value suggests that lofentanil is expected to be immobile in soil. The estimated pKa of lofentanil is 8.36(3), indicating that this compound will exist partially in the cation form in the environment and cations generally adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts(4).
/HUMAN EXPOSURE STUDIES/ Sixty postoperative orthopedic patients were randomly assigned to three equal groups to study, in a double-blind fashion, the analgesic effects, durations of action and side effects of the extradural administration of lofentanil 5 micrograms, buprenorphine 0.3 mg or physiological saline. No systemic analgesics were given before, during or after surgery, and all the patients had operations on the lower extremities under extradural analgesia (lignocaine and bupivacaine). Eleven millilitre of the test drug was injected at T12-L1 as soon as pain occurred in the postoperative period. We observed a long duration of action and a marked analgesic effect with lofentanil, a shorter duration of action and less pain suppression with buprenorphine and a rather marked placebo effect after saline. The only side effect noticed in this study was drowsiness in three patients in the lofentanil group and in two patients in the buprenorphine group.
/HUMAN EXPOSURE STUDIES/ The efficacy and safety of IM lofentanil, the most potent morphinomimetic drug available, for rapid control of postoperative pain was compared with IM piritramide and placebo in a study of 120 patients. Piritramide 7.5 mg and 15 mg, lofentanil 0.25 micrograms, 0.50 micrograms and 0.75 micrograms had a rapid onset of analgesic effect. Significant differences in pain intensity and pain relief when compared to placebo were observed at each observation period for each drug. Piritramide 15 mg is significantly more effective at 4, 5 and 6 hours when compared to lofentanil 0.75 micrograms, thus having a longer lasting effect than lofentanil 0.75 micrograms. There were no significant differences in pain relief between the different doses of lofentanil or between the different doses of piritramide. Side effects of very low incidence included nausea, vomiting and sedation in both piritramide and lofentanil groups.
An estimated BCF of 280 was calculated in fish for lofentanil(SRC), using a log Kow of 4.22(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is high, provided the compound is not metabolized by the organism(SRC).
An estimated pKa of 8.36(1) indicates lofentanil will exist partially in the cation form at pH values of 5 to 9 and, therefore, volatilization of the cation from water and moist soil surfaces is not expected to be an important fate process(SRC). The Henry's Law constant for lofentanil is estimated as 5.8X10-13 atm-cu m/mole(SRC) using a fragment constant estimation method(2). This Henry's Law constant indicates that neutral form of lofentanil is expected to be essentially nonvolatile from water and moist soil surfaces(3). Lofentanil is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 3.5X10-10 mm Hg(SRC), determined from a fragment constant method(2).
/LABORATORY ANIMALS: Neurotoxicity/ Antidromic vasodilatation in the hindpaw skin of rats was studied by laser Doppler flowmetry (LDF). Antidromic stimulation of the saphenous nerve (10 V, 1 ms, 2 Hz, 15 s) increased LDF readings more than two-fold. This increase was abolished by acute nerve section, local lidocain or local 1% capsaicin, augmented by guanethidine (20 mg/kg) and unaffected by atropine (1 mg/kg). While mepyramine plus cimetidine (10 mg/kg each) reduced basal LDF readings, they did not change the percent increase after stimulation. [D-Met2, Pro5] enkephalinamide (3 mg/kg) caused a naloxone-reversible inhibition of the stimulation-induced increase. Lofentanil (10 ug/kg i.v.) also caused an inhibition but this was associated with a marked fall in blood pressure. These results indicate that LDF is a suitable non-invasive method for the indirect measurement of antidromic vasodilatation in rat skin. While opiates appear to inhibit the release of the neurogenic vasoactive mediator(s), histamine is unlikely to be involved in the rapid vasodilator response following antidromic sensory nerve stimulation.
/LABORATORY ANIMALS: Neurotoxicity/ The effects of four anilidopiperidine analgesics, fentanyl, sufentanil, lofentanil and alfentanil on the activity of single neurons in the rat brain stem were examined using the technique of microiontophoresis. Neurons whose discharge rate could be related to respiration and non-respiratory neurons were studied. Alfentanil produced depression of neuronal firing which was slow in onset, shallow and prolonged, similar to the responses seen previously with etorphine. These responses were antagonized by naloxone. The depressant responses to fentanyl, sufentanil, and lofentanil were often different in character, being rapid in onset and of short duration, although slow long lasting responses also occurred and sometimes the two responses were combined. However, only the slow response was blocked by naloxone, the fast, short-duration response being naloxone-resistant. No differences in the responses of respiratory and non-respiratory neurons to these drugs were observed.
/OTHER TOXICITY INFORMATION/ Dose-response relationships for the opiate-induced stimulation of locomotion in mice were determined for etorphine, fentanyl, levorphanol, lofentanil and morphine, both before and after the subcutaneous implantation of a morphine pellet for 3 days. In non-tolerant mice, the relative potencies of these drugs compared to morphine paralleled those reported for other in vivo models of the actions of opiates. The most potent was lofentanil (ED50 = 3.8 ug/kg), which was approx. 6000 times more potent than morphine (ED50 = 24.2 mg/kg). A tolerance-induced 22-fold increase in the ED50 for morphine resulted in a similar cross-tolerance to levorphanol, but there was less cross-tolerance to fentanyl (4-fold), lofentanil (5-fold) and etorphine (7-fold). The smaller cross-tolerances of etorphine and lofentanil to morphine were not accompanied by changes in the levels of (3)H-etorphine or (3)H-lofentanil in brain, induced by morphine pellets, although the bound fraction of (3)H-lofentanil in brain was slightly decreased (11-15%). The implications of the phenomenon of unequal cross-tolerance for the mechanism of tolerance at the opiate mu receptor are discussed.
/OTHER TOXICITY INFORMATION/ Increasing doses of lofentanil (0, 0.08, 0.16, 0.31, 0.63, 1.25, 2.50, 5.00, and 10.0 ug/kg), a potent long-acting narcotic, were administered intravenously to rats to examine the relationship among narcotic dosage, degree of analgesia (inhibition of tail withdrawal reflex), anesthesia (no response to bone-crush injury), and central nervous system (CNS) opiate-receptor occupancy (inhibition of (3)H sufentanil binding). Our results demonstrate that increasing doses of lofentanil produce increasing analgesia and anesthesia and eventually complete opiate receptor occupancy. Analgesia occurs with doses of lofentanil (0.31 ug/kg) that result in levels of CNS opiate-receptor binding too low to be measured and anesthesia occurs with doses of lofentanil (1.25 ug/kg) that produce occupancy of about 25% of the available opiate receptors in subcortical areas and cortex. These findings in rats cannot be applied to narcotic usage in humans, but the data do indicate that in rats a dose eight times the anesthetic dose of lofentanil is needed to saturate virtually all available CNS opiate receptors (10.0 ug/kg). Whether saturation of most or all available CNS opiate receptors during narcotic anesthesia is of clinical importance remains to be determined.
For more Non-Human Toxicity Excerpts (Complete) data for Lofentanil (6 total), please visit the HSDB record page.
A base-catalyzed second-order hydrolysis rate constant of 1.4X10-6 L/mole-sec(SRC) was estimated using a structure estimation method(1); this corresponds to half-lives of 160,000 and 16,000 years at pH values of 7 and 8, respectively(1). Lofentanil contains chromophores that absorb at wavelengths >290 nm(2) and, therefore, may be susceptible to direct photolysis by sunlight(SRC).
Occupational exposure to lofentanil may occur through dermal contact with this compound at workplaces where lofentanil is produced or administered. Exposure to lofentanil among the general population may be limited to those administered the drug or its use as an illicit drug. (SRC)
Lofentanil's production and administration as an analgesic may result in its release to the environment through various waste streams. If released to air, an estimated vapor pressure of 3.5X10-10 mm Hg at 25 °C indicates lofentanil will exist solely in the particulate phase in the atmosphere. Particulate-phase lofentanil will be removed from the atmosphere by wet and dry deposition. Lofentanil contains chromophores that absorb at wavelengths >290 nm and, therefore, may be susceptible to direct photolysis by sunlight. If released to soil, lofentanil is expected to have no mobility based upon an estimated Koc of 30,000. The estimated pKa of lofentanil is 8.36, indicating that this compound will exist partially in the cation form in the environment and cations generally adsorb more strongly to soils containing organic carbon and clay than their neutral counterparts. Volatilization from moist soil surfaces is not expected to be an important fate process based upon the estimated pKa and estimated Henry's Law constant of 5.8X10-13 atm-cu m/mole. Lofentanil is not expected to volatilize from dry soil surfaces based upon its estimated vapor pressure. Biodegradation data in soil or water were not available. If released into water, lofentanil is expected to adsorb to suspended solids and sediment based upon the estimated Koc. Volatilization from water surfaces is not expected to be an important fate process based upon this compound's estimated pKa and Henry's Law constant. An estimated BCF of 280 suggests the potential for bioconcentration in aquatic organisms is high. Hydrolysis is not expected based on estimated hydrolysis half-lives of 160,000 and 16,000 years at pH values of 7 and 8, respectively. Occupational exposure to lofentanil may occur through dermal contact with this compound at workplaces where lofentanil is produced or administered. Exposure to lofentanil among the general population may be limited to those administered the drug or its use as an illicit drug. (SRC)
/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/
/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . /Poisons A and B/
/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W TKO /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's (LR) if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/
Emergency and supportive measures. 1. Maintain an open airway and assist ventilation if necessary. Administer supplemental oxygen. Treat coma, seizures, hypotension, and noncardiogenic pulmonary edema if they occur. /Opiates and opioids/
For more Antidote and Emergency Treatment (Complete) data for Lofentanil (7 total), please visit the HSDB record page.
There was stereospecific binding of (3)H-lofentanil (KD value = 1.53 nM) to membranes of neuroblastoma-glioma NG 108-15 cells which are known to bear high affinity binding sites for enkephalin derivatives (delta-opiate receptor subtype). There was no high affinity specific binding of the mu-opiate specific ligand (3)H-sufentanil. The specific binding of (3)H-lofentanil to delta-opiate receptor subtype was down-regulated (decrease in Bmax value without change in the KD value) after prolonged incubation of the cells in the presence of leu- and met- enkephalin (0.1 uM). There was no down-regulation of the opiate receptors (3)H-lofentanil and (3)H-D-ala-D-leu-enkephalin specific binding) after incubation of NG 108-15 cells with drugs from the fentanyl series (alfentanil or sufentanil). In cultured neurones from rat forebrain (15 day old embryos), the (3)H-lofentanil binding was specific with high affinity (KD: 0.048 nM) and a slow dissociation rate similar to that in adult rat cortex. Drugs of the fentanyl series (4-anilino-piperidines) were potent displacers whereas agonists of the delta- (enkephalin derivatives), sigma- (phencyclidine, haloperidol, 3-hydroxyphenyl-propylpiperidine) or K- (U 50488) opiate sites had a low affinity (Ki greater than 0.5 uM) for (3)H-lofentanil specific binding sites. Since there was also specific binding of (3)H-sufentanil, the opiate receptors in cultured neurones seem to be mainly of the mu-subtype and this is consistent with the ontogeny of opiate receptors subtypes. These receptors were down-regulated after incubation in the presence of etorphine, sufentanil and alfentanil but not enkephalin derivatives.
(3)H-Lofentanil, an extremely potent opiate drug with a very long duration of action was injected intravenously into rats immediately after a ligature had been tied around the vagus nerve. Radioactivity accumulated on both sides of the ligature 24 hours and, to a larger extent, 48 hours after the injection. In contrast, there was no accumulation in animals pretreated with naloxone, neither in ligated sciatic nerves nor between two ligatures in the vagus nerve. An accumulation of stereospecific (3)H-lofentanil binding sites measured in vitro was only detected above the ligature, thus in the proximal part of the nerve. When (3)H-lofentanil was injected at different time intervals after ligation, we observed a tremendous drop of labelling in the distal and also but more slowly in the proximal part of the nerve. This could be due to a possible recycling or re-utilization of (3)H-lofentanil binding sites. The present data are compatible with an axoplasmic flow and a possible recycling of opiate receptors labelled in vivo after intravenous injection of (3)H-lofentanil.
The in vivo binding of (3)H-lofentanil was studied in various regions of the brain in rat. After intravenous injection of (3)H-lofentanil the disposition of the labelled drug in the brain paralleled exactly the regional distribution of opiate receptors measured in in vitro binding assays. The labelling was saturable and could be prevented by naloxone when given before (3)H-lofentanil, in all the regions except in the cerebellum. The long-lasting occurrence of the specific labelling was entirely compatible with the extremely slow dissociation rate of lofentanil and its long duration of action. This explains why (3)H-lofentanil is not displaceable by naloxone in vivo. Subcellular fractionation experiments revealed that all the labelling in the frontal cortex but not in the cerebellum was particulate-bound and entirely displaceable by naloxone. The advantages of (3)H-lofentanil in vivo are its extremely low non-specific binding and its ability to reveal very low occupancy of opiate receptors in brain.
The in vitro plasma protein binding and distribution in blood of fentanyl and three analogues were studied in rats, dogs and healthy volunteers. In human plasma, 84.4% of fentanyl was bound, 92.5% of sufentanil, 92.1% of alfentanil and 93.6% of lofentanil. Plasma protein binding of the four analgesics was independent of their concentration over the whole therapeutic range. Plasma protein binding of alfentanil was much less pH dependent than that of the three other analgesics. Attention was drawn to the possible contribution of the "acute phase" protein alpha 1-acid glycoprotein (alpha 1-AGP), of lipoproteins and of blood cells to the binding of fentanyl and its analogues in blood.
The influence of the pH of the incubation medium on the cellular accumulation of tritiated fentanyl, lofentanil, and alfentanil was investigated in isolated guinea pig atria. Fentanyl and lofentanil accumulated in atrial tissue up to about 30- and 50-fold, respectively. The amount of drug bound when equilibrium was attained was found to be dependent upon the pH of the medium. By plotting binding equilibria v. pH of the bath, curves were obtained which resembled titration curves. Half-maximal binding was attained at pH values close to the pKa values of fentanyl and lofentanil. Alfentanil was found to accumulate less. The uptake by the tissue was strongly proportional to the extracellular concentration. Atria equilibrated with fentanyl at pH 8.5 released the compound rapidly when exposed to a pH of 7.0, even in the continuous presence of fentanyl in the bath. The consequences of the findings for in vivo conditions are discussed with respect to a possible augmentation of the actions of fentanyl by respiratory acidosis.
Very potent opioid analgesic.
Analgesics, Opioid
UsesAnalgesic (narcotic). Controlled Substance